Genprex (GNPX) Research & Development (2016 - 2026)
Genprex (GNPX) posted quarterly Research & Development of $408834.0 for Q1 2026, up 32.6% year-over-year from $308327.0 in Q1 2025, and down 95.18% quarter-over-quarter from $8.5 million in Q4 2025.
Genprex (GNPX) Research & Development (2016 - 2026) Analysis & Trends
Genprex's Research & Development history runs 11 years deep, the most recent figure standing at $408834.0 for Q1 2026.
- In Q1 2026, Research & Development rose 32.6% year-over-year to $408834.0; the TTM figure through Mar 2026 stood at $9.5 million (down 10.13% YoY), while the FY2025 annual figure was $9.4 million, down 10.5% from the prior year.
- Research & Development for Q1 2026 stood at $408834.0, down from $8.5 million in the prior quarter.
- The five-year high for Research & Development was $10.3 million in Q4 2024, with the low at -$243915.0 in Q2 2024.
- The 5-year median for Research & Development is $3.2 million (2022), against an average of $3.1 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development sank 106.13% in 2024, then surged 234.88% in 2025.
- Genprex's Research & Development stood at $3.4 million in 2022, then climbed by 9.68% to $3.7 million in 2023, then soared by 177.37% to $10.3 million in 2024, then slipped by 17.68% to $8.5 million in 2025, then tumbled by 95.18% to $408834.0 in 2026.
- Business Quant data shows GNPX's Research & Development at $408834.0 in Q1 2026, $8.5 million in Q4 2025, and $313323.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Genprex | 1.89 Mn | -13.27 Mn | - | 703,221.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 408,834.00 |
| Dec 31, 2025 | 8.48 Mn |
| Sep 30, 2025 | 313,323.00 |
| Jun 30, 2025 | 328,991.00 |
| Mar 31, 2025 | 308,327.00 |
| Dec 31, 2024 | 10.30 Mn |
| Sep 30, 2024 | 240,701.00 |
| Jun 30, 2024 | -243,915.00 |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | 3.71 Mn |
| Sep 30, 2023 | 4.62 Mn |
| Jun 30, 2023 | 3.98 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | 2.93 Mn |
| Mar 31, 2022 | 2.04 Mn |
| Dec 31, 2021 | 3.84 Mn |
| Sep 30, 2021 | 1.43 Mn |
| Jun 30, 2021 | 1.53 Mn |